Best Investments In 2014

Is Gilead Sciences (GILD) in correction mode?

Recently at $104.03, the biotech giant fell 2.7% today, extending a slide that began in late October when the stock hit a 52-week high. Gilead has since fallen 11%.

RBC analyst Michael Yee attributes the recent weakness to media reports about patents for a rival hepatitis C drug and comments about increased scrutiny from insurance companies regarding the use of new Hepatitis C therapies.

Yee writes:

To be clear, these types of comments may cause some headline concern but are not new. For example (1) please see our August 30, 2013 GILD report (“Looking at the ABBV HCV Patents…Seems More Bark Than Bite”). ABBV is claiming a patent for someone else’s drugs. A) GILD already has published and pending patents for this, B) in some instances GILD filed before ABBV (filing first typically can determine precedence); (2) the payor comments aren’t new, these drugs already required prior auth.

Top 5 Cheapest Companies To Own In Right Now: Ensign Group Inc (ENSG)

The Ensign Group, Inc., incorporated in 1999, is a holding company. The Company is a provider of skilled nursing and rehabilitative care services through the operation of 103 facilities, five home health and three hospice operations located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Oregon, Texas, Utah and Washington. Its facilities provide a spectrum of skilled nursing, assisted living, home health and hospice services, including physical, occupational and speech therapies, and other rehabilitative and healthcare services, for both long-term residents and short-stay rehabilitation patients. Its walk-in clinics will offer daily access to healthcare for minor injuries and illnesses, including x-ray and lab services, all from convenient neighborhood locations with no appointments. In March 2014, the Company acquired Horizon Post-Acute and Rehabilitation Center, a 196-bed skilled nursing facility in Glendale, Arizona.

On January 1, 2011, the Company purchased one skilled nursing facility which also offers assisted living and independent living services and one independent living facility. On February 1, 2011, the Company purchased one skilled nursing facility in Utah, which also offers assisted living and independent living services. On March 18, 2011, the Company purchased one assisted living facility in California. On May 15, 2011, the Company purchased a home health and hospice operation in Utah. On June 1, 2011, the Company purchased an assisted living facility in Nevada. On July 18, 2011, the Company acquired nine skilled nursing facilities. On August 1, 2011, the Company acquired a skilled nursing facility in Texas; the Company acquired a skilled nursing facility in Utah, and the Company acquired an independent living facility. On October 1, 2011, the Company acquired a skilled nursing facility in California. On December 1, 2011, the Company acquired a skilled nursing facility in Nevada. On December 30, 2011, the Company acquired an assisted living facility in Ari! zona. In November 2011, the Company acquired Pocatello Care and Rehabilitation Center. On November 22, 2011, the Company acquired Homecare Solutions.

The Company's facilities provide a range of skilled nursing and assisted living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services, for both long-term residents and short-stay rehabilitation patients. As of December 31, 2011, it operated 102 facilities, of which it owned 77 and operated an additional 25 facilities under long-term lease arrangements, and had options to purchase five of those 25 facilities.

The Company's wholly owned subsidiaries, which include the Service Center, provides centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company's operating subsidiaries for general and professional liability, as well as coverage for some workers' compensation insurance liabilities.

Skilled nursing facility revenue is primarily derived from Medicaid, private pay, managed care and Medicare payors. The Company�� skilled nursing facilities provide Medicaid-covered services to individuals consisting of nursing care, room and board and social services. Rehabilitation therapy revenue is primarily received from private pay and Medicare for services provided at skilled nursing facilities and assisted living facilities. Assisted living facility revenue is primarily derived from private pay residents. In addition, Medicaid or other programs in some states where it operates supplement payments for board and care services provided in assisted living facilities. Hospice revenues are primarily derived from Medicare. It derives substantially all of the revenue from its home health busines! s from Me! dicare and Managed Care sources. Its home health care services generally consist of providing some combination of the services of registered nurses, speech, occupational and physical therapists, medical social workers and certified home health aides.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Ensign Group (Nasdaq: ENSG  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Ensign Group (Nasdaq: ENSG  ) , whose recent revenue and earnings are plotted below.

• [By Eric Volkman]

  Ensign Group (NASDAQ: ENSG  ) has a new asset in its medicine chest. The company announced that, at the end of June, it had closed the acquisition of the Mountain View Rehabilitation and Care Center in Washington state. The center is an 82-bed skilled nursing facility located in the town of Marysville. The terms of the deal were not disclosed, although Ensign Group admitted that the purchase was effected in cash.

Best Investments In 2014: Trovagene Inc (TROV)

TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.

On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.

In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Advisors' Opinion:

• [By Roberto Pedone]

  TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.

  Friday's Volume: 712,000
  
  Three-Month Average Volume: 183,106
  
  Volume % Change: 294%

  From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.

  Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.

• [By David Goodboy]

  Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).

• [By Daniel Lauchheimer]

  In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.

Best Investments In 2014: Cermaq ASA (CEQ)

Cermaq ASA is a Norway-based company active in the aquaculture industry. It is engaged in the farming of salmon and trout. The Company, along with its subsidiaries, operates in one business segment, namely Aquaculture, which consists of two divisions: Fish Feed production, which involves the production and sale of fish feed, and Fish Farming, which involves the breeding and on-growing, as well as the slaughtering, processing, sale and distribution of salmon and trout. The Company�� other activities consist of operations carried out through its subsidiary, Norgrain AS, the associated company, Denofa AS and the parent company. The Company operates through its subsidiaries, including Statkorn Aqua AS and Mainstream Norway AS, among others. In October 2013, the Company sold its second business segment, EWOS Group, to Altor Fund III and Bain Capital. Advisors' Opinion:

• [By Chuck Carnevale]

  Additional strengths supporting Aflac�� business model can be found by reviewing their common equity or book value (ceq), the lime green line on the following graph, in comparison to their current market value (mkval), the aqua colored more jagged line on the graph. Aflac�� book value has increased steadily except for a minor pause during the Great Recession of 2008. In contrast, their market value has been much more cyclical and erratic. I believe this additionally reflects current undervaluation of Aflac�� shares. This further supports my contention that Aflac is a great business that is currently on sale.

Best Investments In 2014: HD Supply Holdings Inc (HDS)

HD Supply Holdings, Inc., incorporated on June 18, 2007, is an industrial distributor in North America. It operates in four segments: Facilities Maintenance, Waterworks, Power Solutions and White Cap. Facilities Maintenance distributes maintenance, repair and operations (MRO) products, provides value-add services and fabricates custom products to multifamily, hospitality, healthcare and institutional facilities. Waterworks distributes complete lines of water and wastewater transmission products, serving contractors and municipalities in the water and wastewater industries for non-residential and residential uses. Power Solutions distributes electrical transmission and distribution products, power plant MRO supplies and smart-grid products, and arranges materials management and procurement outsourcing for the power generation and distribution industries. White Cap distributes specialized hardware, tools, engineered materials and safety products to non-residential and residential contractors.

Maintenance, Repair & Operations

In the Maintenance, Repair & Operations market sector, the Company�� Facilities Maintenance, Crown Bolt and Repair & Remodel business units serve customers across multiple industries by primarily delivering supplies and services needed to maintain and upgrade multifamily, hospitality, healthcare and institutional facilities. Facilities Maintenance and Crown Bolt are distribution center based models, while Repair & Remodel operates through retail outlets primarily serving cash and carry customers.

Infrastructure & Power and Specialty Construction

In the Infrastructure & Power market sector, Waterworks and Power Solutions support both established infrastructure and new projects by meeting demand for critical supplies and services used to build and maintain water systems and electrical power generation, transmission and distribution infrastructure. In the Specialty Construction market sector, White Cap and Creative Touch Interiors (! CTI) serve professional contractors and trades by meeting their distinct and customized supply needs in non-residential, residential and industrial applications. White Cap is its primary business unit serving this sector through the broad national presence of its regionally organized branch distribution network.

Advisors' Opinion:

• [By Mani]

  The long-term set up for HD Supply Holdings Inc (NASDAQ:HDS) appears to be favorable, primarily driven by prospective U.S. non-residential construction recovery and rapid balance sheet deleveraging in the future.